Guidelines for prostate cancer treatmentdoi:10.1016/S0140-6736(95)92495-7DavidH. FrankelThe Lancet
Nearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable features. These pat
Currently, most prostate cancer treatment guidelines worldwide recommend an observation-based approach, primarily active surveillance, for such cases, resembling a treatment model for precancerous conditions rather than curative treatment for the majority of cancers26,27. In the 12 cases with a PI-...
Cells treated with I mu M Aplidin for 24 h then killed by 100 Gy of radiation were toxic to untreated cells co-cultured with them. Conclusions: The cytotoxicity of Aplidin is independent of the oxygenation during treatment. Aplidin, or an active metabolite of Aplidin, is retained in the ...
Cite this: ESMO 2023: Advancing Prostate Cancer Care - Medscape - Oct 27, 2023.Recommendations Understanding Functional Outcomes in Prostate Cancer news Prostate Cancer Treatment Associated With More Complications news Optimizing Outcomes for Patients With NMIBC: Challenges and Recent Developments in Cl...
(PDT) is also an approach for the treatment of cancer which promotes the generation of reactive oxygen species in cancer cells leading to the induction of apoptosis in cancer cells [155,156]. Polymer-coated metal nanostructures have been used for the PDT. It has also been employed for ...
The induction of “protective autophagy” by cancer cells is a well-known response to stress or anti-cancer drug treatment. This can be overcome by adding an autophagy inhibitor drug, such as propranolol. (DCA synergy with the autophagy inhibitor propranolol is discussed below.) In addition, Dr...
(i.e., false-positives results that require additional testing and possible prostate biopsy, overdiagnosis, overtreatment, and treatment complications such as erectile dysfunction and urinary difficulties). In regard to age and the effectiveness of PSA-based screening and prostate cancer mortality, ...
Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relatives. There are various guidelines and consensus stat...
An Author Correction to this article was published on 22 February 2023This article has been updatedAbstract Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient’s optimal therapy is a challenge, where oncologists must select a therapy ...